Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation plc (NASDAQ: PRTA) is described in its own press releases as a late-stage clinical biotechnology company focused on protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. The PRTA news feed on Stock Titan aggregates these company communications, giving investors and observers a single place to follow Prothena’s disclosures and milestones.
In its recent news, Prothena has highlighted progress across a pipeline that includes both wholly-owned and partnered programs. Updates have covered clinical development for Parkinson’s disease through the prasinezumab collaboration with Roche, ATTR amyloidosis with cardiomyopathy via coramitug (formerly PRX004) now being developed by Novo Nordisk, and Alzheimer’s disease programs such as BMS-986446 (formerly PRX005) with Bristol Myers Squibb, PRX012, and the dual Aβ/tau vaccine PRX123. The company has also issued releases on its CYTOPE technology platform, workforce restructuring, and financial results.
Readers of the PRTA news page can review press releases on topics such as Phase 2 and Phase 3 trial plans, Fast Track designations, preclinical data from the TDP-43 CYTOPE program, and corporate actions including an Extraordinary General Meeting to approve a capital reduction to create distributable reserves. Governance and leadership updates, such as changes to the Board of Directors, are also disclosed through these announcements.
By following this curated stream of Prothena’s own news, users can see how the company presents the status of its investigational therapeutics, collaborations with partners like Roche, Novo Nordisk and Bristol Myers Squibb, and its capital and cost structure decisions. The PRTA news page is intended as a convenient starting point for reviewing Prothena’s publicly released information over time.
Prothena Corporation (NASDAQ:PRTA) announced encouraging results from the Phase 2 PASADENA study of prasinezumab, an anti-alpha-synuclein antibody aimed at early Parkinson's disease. Although the primary endpoint was not met, significant efficacy signals were observed, including a 35% reduction in motor function decline compared to placebo after one year. The drug also delayed clinically meaningful worsening of motor progression. These results support further clinical development of prasinezumab as a potential disease-modifying therapy, with an investor webcast scheduled for September 15, 2020.
Dublin, Ireland - Prothena Corporation plc (NASDAQ: PRTA) announced that its senior management team will speak at the 2020 Cantor Virtual Global Healthcare Conference on September 15, 2020, at 4:00 PM ET. A webcast of the presentation will be accessible on the company's investor relations website, with a replay available for 90 days post-event. Prothena focuses on developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, with programs targeting conditions like Alzheimer’s, ALS, and Parkinson's disease.
Prothena Corporation (NASDAQ: PRTA) updated the presentation timing for results from Part 1 of the Phase 2 PASADENA study involving prasinezumab for early Parkinson's disease. The oral presentation, originally set for September 14, will now be on September 15 at the 2020 International Congress of Parkinson’s Disease and Movement Disorders Society. Prasinezumab, a humanized monoclonal antibody, targets alpha-synuclein to potentially slow clinical decline in Parkinson's patients. Prothena has partnered with Roche for its development, sharing costs and profits on a 30/70 basis.
Prothena Corporation (NASDAQ:PRTA) reported a net loss of $26.3 million for Q2 2020, significantly higher than $15.8 million in Q2 2019. Total revenue for Q2 remained stable at $0.2 million. The company’s cash position is strong, with $336.6 million available to fund ongoing R&D efforts. Upcoming milestones include presentations of clinical data for their Parkinson’s disease treatment, prasinezumab, and updates on PRX004 for ATTR amyloidosis. Prothena expects full-year cash burn between $75-$85 million, predicting an end-of-year cash position of approximately $299 million.
Prothena Corporation (NASDAQ: PRTA) announced that results from Part 1 of the Phase 2 PASADENA study on prasinezumab for early Parkinson’s disease were selected as an oral Top Abstract at the International Congress of Parkinson’s Disease and Movement Disorders Society (MDS). This session will take place on September 14, 2020, with a poster also displayed in the virtual hall. Prasinezumab aims to block the transmission of aggregated alpha-synuclein, potentially slowing disease progression. Prothena continues its collaboration with Roche, focusing on achieving significant milestones.
Prothena Corporation plc (NASDAQ: PRTA) will announce its Q2 and H1 2020 financial results on August 6, after U.S. market close. The company specializes in neurodegenerative and rare peripheral amyloid diseases, with a pipeline of investigational therapeutics. Notably, Prothena collaborates with Roche on prasinezumab for Parkinson’s disease and partners with Bristol-Myers Squibb on therapies targeting Alzheimer’s and other diseases. Consistent with previous practices, there will be no conference call following the earnings release.
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) announced its senior management will present at the Jefferies Virtual Healthcare Conference on June 3 at 3:30 PM ET. Investors can access the presentation via the investor relations section of the company's website. A replay will be available for 90 days post-presentation. Prothena focuses on the discovery of therapies for diseases related to protein misfolding, including Alzheimer's and Parkinson's, with a diverse pipeline of partnered and proprietary programs.
Prothena Corporation reported a net loss of $23.6 million for Q1 2020, compared to $20.9 million in Q1 2019, with a net loss per share of $0.59. Total revenue from its collaboration with Roche was only $0.1 million, down from $0.2 million. R&D expenses rose to $15.2 million due to collaboration costs and clinical trials. The cash position remains strong at $355.4 million, but the net cash burn for 2020 is estimated at $75 to $85 million, up from previous guidance. Prothena has ongoing evaluations for its drug programs, including prasinezumab.